论文部分内容阅读
目的观察依达拉奉治疗脑梗死的效果,并分析其对患者血清高迁移率族蛋白-1及S100β蛋白水平的影响。方法研究对象为2011年1月-2014年7月就诊的脑梗死患者94例,根据入院顺序随机分为治疗组和对照组,每组47例。另选同期健康体检者47例作为对照组。治疗1组、治疗2组均给予脱水降颅内压、抗血小板聚集、控制血压、调脂及补液等治疗。治疗1组在以上治疗基础上加依达拉奉注射液30 mg+0.9%氯化钠溶液100 ml静脉滴注,2次/d,连续使用14 d。结果治疗前治疗1组、治疗2组血清HMGB1、S100β水平[(11.64±2.07)、(11.96±2.41)mg/L、(5.69±0.39)、(5.87±0.54)μg/L]均高于对照组[(0.96±0.35)mg/L、(0.89±0.51)μg/L],比较差异有统计学意义(P<0.05);治疗1组、治疗2组治疗后7、14d血清HMGB1、S100β水平[(4.55±1.21)、(6.97±1.04)、(2.04±0.53)、(3.87±0.62)mg/L、(2.67±0.39)、(3.84±0.37)、(1.12±0.09)、(2.04±0.33)μg/L]与同组治疗前比较差异有统计学意义,两组间比较差异也有统计学意义。两组治疗后7、14、21d NIHSS评分[(10.30±3.82)、(11.87±3.84)、(7.03±2.35)、(9.23±2.94)、(4.50±1.39)、(6.67±2.08)分]与同组治疗前[(13.97±5.03)、(13.68±5.30)分]比较差异有统计学意义(P<0.05),两组间治疗后14、21d比较差异也有统计学意义(P<0.05)。结论依达拉奉可降低脑梗死患者HMGB1、S100β水平,改善其神经功能。
Objective To observe the effect of edaravone in the treatment of cerebral infarction and analyze its effect on serum high mobility group box-1 and S100β protein in patients. Methods 94 patients with cerebral infarction from January 2011 to July 2014 were randomly divided into treatment group (n = 47) and control group (n = 47). In the same period, 47 healthy subjects were selected as the control group. Treatment 1 group, treatment 2 groups were given dehydration and intracranial pressure, anti-platelet aggregation, control of blood pressure, lipid-lowering and rehydration therapy. Treatment group 1 in addition to the above treatment plus edaravone injection 30 mg + 0.9% sodium chloride solution 100 ml intravenous infusion, 2 times / d, continuous use 14 d. Results The levels of serum HMGB1 and S100β in the two groups before treatment were significantly higher than those in the control group [(11.64 ± 2.07), (11.96 ± 2.41) mg / L, (5.69 ± 0.39), (5.87 ± 0.54) μg / L] (0.96 ± 0.35) mg / L, (0.89 ± 0.51) μg / L], the difference was statistically significant (P <0.05). The levels of serum HMGB1, S100β in the treatment group 1 and treatment group 2 (4.55 ± 1.21, 6.97 ± 1.04, 2.04 ± 0.53, 3.87 ± 0.62 mg / L, 2.67 ± 0.39, 3.84 ± 0.37, 1.12 ± 0.09, 2.04 ± 0.33, ) μg / L] with the same group before treatment, the difference was statistically significant, the difference between the two groups was also statistically significant. The NIHSS scores at the 7th, 14th, and 21st day after treatment in the two groups were significantly higher than those in the control group (P <0.01) There were significant differences between the two groups before treatment [(13.97 ± 5.03), (13.68 ± 5.30) points] (P <0.05). There was also significant difference between the two groups on the 14th and 21st days after treatment (P <0.05). Conclusion Edaravone can reduce the levels of HMGB1 and S100β in patients with cerebral infarction and improve their neurological function.